ArticleNPJ biofilms and microbiomes2025
Microanatomy related biocidal activity at cellular resolution and bone reconstruction potential of PEG EGaIn nanocapsules.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Critical bone defects, exacerbated by infections, pose significant challenges to bone healing and homeostasis, necessitating the development of dual-functional biomimetics that combine anti-infective and reparative capabilities. The EGaIn holds promise across various disciplines, though its interactions with microbial cells require further elucidation. This investigation evaluates the antimicrobial efficacy of PEG-EGaIn nanocapsules against a spectrum of bacterial, employing electron microscopy. Constructs containing 1.5% PEG-EGaIn hinder biofilm-producing bacteria, while 3% concentrations amplify the biocidal effect. Furthermore, the nanocapsules promoted osteogenic differentiation rBMSCs, evidenced by enhanced mineralization and upregulation of key osteogenic genes. In addressing large bone defects, PEG-EGaIn-Col-Ap-lamellar and ethanolic-mediated Col-Ap-lamellar constructs serve as potential solutions for bone resorption mitigation and osteo-angiogenesis. Bone-remodeling were validated through μ-CT and histomorphometry confirming no evidence of chronic inflammation or fibrosis. In this study, PEG-EGaIn nanocapsules emerge as potent biocide and bone repair, underscoring their potential in combating antibiotic resistance and enhancing bone healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.